CINCINNATI--(BUSINESS WIRE)--Meridian Bioscience, Inc. (NASDAQ:VIVO) is pleased to announce the launch of a new Clostridium difficile rapid test, ImmunoCard C. difficile GDH. This assay detects the ...

Pro-Lab Diagnostics has launched a high quality immunoassay for rapid and accurate screening of patients with suspected Clostridium difficile infection. The Prolisa™ C. difficile GDH (glutamate ...

Thu, January 5, 2012 at 2:30 PM UTC ImmunoCard C. difficile GDH is geared to detect a common antigen, known as Glutamate dehydrogenase (“GHD”), produced by the toxigenic and non-toxigenic forms of C.

Lewis, J. (2009) Exploring the accuracy and practicality of a new two-step algorithm for C. difficile testing. Nursing Times; 105: 16, early online publication. C. difficile infection is a major cause ...

The presence of antigen-specific and neutralizing antibodies was not associated with Clostridioides difficile infection symptoms, severity, therapy approach, treatment response, or recurrences in a ...

The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical ...

A new review looks at the challenges of testing for Clostridioides (Clostridium) difficile infection (CDI) and recommendations for newer diagnostic tests. Accurate diagnosis of CDI is critical for ...

Meridian Bioscience Inc. (NASDAQ: VIVO), the Cincinnati, Ohio diagnostic test maker, has received FDA clearance for its new Clostridium difficile test. The ImmunoCard C. difficile GDH test has already ...

Diagnostics company Meridian Bioscience (NASDAQ:VIVO) plans to launch a new C. difficile test in Europe. C. difficile is a bacterium that can cause symptoms ranging from diarrhea to life-threatening ...

OpenBiome reported that it is collaborating with the University of Minnesota’s Microbiota Therapeutics Program (MTP) to ensure that patients with recurrent Clostridium difficile (C. difficile) ...

The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical ...